drugset / Trial / NCT05551767
Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer
Phase 2
Unknown
120 enrolled
City Clinical Oncology Hospital No 1
Moscow City Oncology Hospital No. 62 · collabMoscow Clinical Scientific Center · collab
NaSingle-groupOpen-labelTreatment
Summary
patients with locally advanced cancer of oropharynx, hypopharynx or larynx and CPS\>1 will recieve 3 cycles of induction immunochemotherapy with platinum, 5-FU and pembrolizumab followed by (chemo)radiation.
Timeline
- Start
- 2022-08-30
- Primary completion
- 2023-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |